XenoPort to Present at Upcoming Healthcare Conferences

  XenoPort to Present at Upcoming Healthcare Conferences

RBC Capital Markets Global Healthcare Conference 2013 Citi Global Healthcare
Conference 2013

Business Wire

SANTA CLARA, Calif. -- February 19, 2013

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via
the World Wide Web to its presentations at the RBC and Citigroup 2013
Healthcare Conferences. The live presentations will occur at the following
dates and times:

RBC Capital Markets Healthcare Conference February 26 4:05 pm EST

Citi Global Healthcare Conference February 27 9:35 am EST

To access the live presentations via the Web, please go to www.XenoPort.com.
Please connect to the Web site at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may be
necessary to listen to the Webcast.

A replay of each of the Webcasts can be accessed for a minimum of one month
and will be available approximately 24 hours after the live presentation.

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates for
the potential treatment of neurological disorders. Horizant® (gabapentin
enacarbil) Extended-Release Tablets is approved in the United States for the
treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults
and for the management of postherpetic neuralgia in adults. GlaxoSmithKline
holds commercialization rights for Horizant in the United States during a
transition period ending on April 30, 2013, following which XenoPort will be
responsible for the further development, manufacturing and commercialization
of Horizant. Regnite® (gabapentin enacarbil) Extended-Release Tablets is
approved and is being marketed for the treatment of RLS in Japan. Astellas
Pharma Inc. holds all development and commercialization rights for Regnite in
Japan and five other Asian countries. XenoPort holds all other world-wide
rights to gabapentin enacarbil. XenoPort’s pipeline of product candidates
includes potential treatments for patients with spasticity, Parkinson’s
disease and relapsing-remitting multiple sclerosis. To learn more about
XenoPort, please visit the Website at www.XenoPort.com.

Horizant, Regnite and XENOPORT are registered trademarks of XenoPort, Inc.

XNPT2G

Contact:

XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com
 
Press spacebar to pause and continue. Press esc to stop.